Effect of post‐procedural evidence‐based therapy on 2‐year prognosis after transcatheter mitral valve repair.

Autor: Hagnäs, Magnus J., Grasso, Carmelo, Di Salvo, Maria Elena, Sardone, Andrea, Rapisarda, Paola, Pelliccia, Matteo, Dipasquale, Francesco, Castania, Giuseppe, Mangiafico, Sarah, Capranzano, Piera, Barbanti, Marco, Denaro, Alessandro, Scandura, Salvatore, Mäkikallio, Timo, Capodanno, Davide, Tamburino, Corrado
Předmět:
Zdroj: European Journal of Heart Failure; Apr2021, Vol. 23 Issue 4, p677-679, 3p, 1 Chart, 1 Graph
Abstrakt: Guidelines recommend the use of neurohormonal antagonists for all patients with heart failure and mitral regurgitation (MR) as an initial treatment strategy.1,2 Patients with symptoms despite maximally tolerated neurohormonal antagonist treatment, evidence-based therapy (EBT), and moderate-to-severe MR who are surgery-ineligible may undergo transcatheter mitral valve repair with the MitraClip (Abbott Vascular, Abbott Park, IL, USA) system. Patients undergoing the MitraClip procedure for secondary MR with EBT are at lower risk of death compared to patients without EBT. In the era of surgical and transcatheter treatment options, the importance of medications may be neglected when severe MR is present in a patient with heart failure. [Extracted from the article]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje